Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access
October 2021 Newsletter
October 1, 2021
Yemaachi Biotech, Lucence Aim to Improve Genomic Breast Cancer Testing in Ghana and Beyond
November 3, 2021
Close up of biologist's hands with blood sample in the lab
Companies’ work part of a long-term commitment to diversifying clinical trials and expanding access to precision diagnostics globally
PALO ALTO, Calif. & ACCRA, Ghana–(BUSINESS WIRE)–Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.
Read the full press release here.
Image credits: www.lucence.com
Related posts
March 21, 2022
